Boehringer Ingelheim, Pfizer to co-promote Spiriva

Boehringer Ingelheim and Pfizer will globally co-promote BI's Spiriva (tiotropium), a once daily, inhaled bronchodilator to treat chronic obstructive pulmonary disease (COPD), which includes chronic bronchitis and emphysema. Smoking mostly causes the disorder, which causes permanent damage to lung tissue. According to a source from BI, the term of the contract will probably be less than eight years.